Local Researcher Makes Leading Contributions to Study on Impact of Treatment in Cancer Patients
Study published in Leading Science Journal Demonstrates Early Safety and Efficacy of Pirtoburtinib, a Reversible Protein Blocker in Patients Previously Treated for B-cell Malignancies
Milwaukee, April 29, 2021 – In an international, multi-center, phase I/II clinical trial, scientists tested Pirtoburtinib, a new protein Bruton tyrosine kinase (BTK) inhibitor in patients with various B-cell malignancies, where other treatments (including covalent BTK inhibitors) had been ineffective. Researchers found Pirtobrutinib was safe and active in multiple B-cell malignancies, and trial results published in The Lancet suggest the drug could address a growing and unmet need for alternative therapies for these patients. Specifically, the two main indications were for the B-cell malignancies of Chronic lymphocytic leukemia and Mantle Cell lymphoma.
“In many cases, we’re looking for a drug like Pirtobrutinib to act as a bridge to get patients to other advanced treatments such as CAR T-cell therapy or stem cell transplant. What we found was Pirtobrutinib achieved longer-term benefits and remission, among some patients in the study,” said Nirav Shah, MD, MSHP, a leading investigator of the trial, and associate professor of Hematology and Oncology at the Medical College of Wisconsin (MCW), and lymphoma and stem cell transplant specialist at the Froedtert & MCW Cancer Center.
MCW was one of only 30 sites in the world – and the only cancer center in the Midwest – selected to participate in the industry-sponsored* study. Dr. Shah said he’s hopeful MCW’s continued collaborations with top cancer centers and leading researchers will accelerate the advancement and availability of alternative cancer therapies for patients in need.
Funding for the study was provided by Loxo Oncology. This trial is registered with ClinicalTrials.gov, NCT03740529.
Keep up with the latest news. Sign up for Newsroom Alerts.
Latest press releases, stories and resources.